Glenmark Pharmaceuticals Ltd 2020 SR
The report for Glenmark Pharmaceuticals Limited for the fiscal year 2019-2020 highlights the company's commitment to the triple bottom line approach. Key achievements include the launch of FabiFlu (Favipiravir) for COVID-19 treatment and Remogliflozin for diabetes in India. The company reported a 35% increase in solvent recovery and achieved zero liquid discharge at five facilities. Socially, Glenmark impacted approximately 2 million lives through community development programs and maintained zero workplace fatalities. The report follows GRI Standards: Core option and includes external assurance by DNV GL.
Company: Glenmark Pharmaceuticals Ltd
Sector: Manufacturing
Country: India
Year: 2020
Type: SR
Pages: 108
Back to company
Glenmark Pharmaceuticals Ltd
Sustainability Report
The report for Glenmark Pharmaceuticals Limited for the fiscal year 2019-2020 highlights the company's commitment to the triple bottom line approach. Key achievements include the launch of FabiFlu (Favipiravir) for COVID-19 treatment and Remogliflozin for diabetes in India. The company reported a 35% increase in solvent recovery and achieved zero liquid discharge at five facilities. Socially, Glenmark impacted approximately 2 million lives through community development programs and maintained zero workplace fatalities. The report follows GRI Standards: Core option and includes external assurance by DNV GL.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2020
Reporting Period
Apr 1, 2019 - Mar 31, 2020
Fiscal Year
2020
Published
Aug 26, 2020
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Sustainable Development Goals
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Workplace Fatalities
Employees